Peptide Trial Roundup: TRIUMPH-4, SYNCHRONIZE-1, and Pediatric GLP-1 Progress (May 2026)

The second half of May 2026 brings a wave of phase 3 trial readouts that are reshaping expectations for obesity, metabolic disease, and beyond. Eli Lilly's retatrutide delivered 28.7% average weight loss in TRIUMPH-4, the highest figure reported in any phase 3 obesity trial to date. Boehringer Ingelheim's survodutide posted 16.6% weight loss in SYNCHRONIZE-1. Novo Nordisk launched Ozempic tablets nationwide on May 4 and reported positive results for oral semaglutide in children with type 2 diabetes. Meanwhile, early-stage research on brain injury, Alzheimer's disease, and metastatic cancer peptides is advancing toward human trials.

This roundup covers the major clinical developments from late April through mid-May 2026, with a focus on what the data actually shows and what comes next.

What Did the TRIUMPH-4 Trial Show About Retatrutide?

Retatrutide is Eli Lilly's investigational triple receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. The TRIUMPH-4 trial, announced in December 2025, tested retatrutide in 445 adults with obesity and knee osteoarthritis over 68 weeks.

Weight Loss Results

Participants receiving the 12 mg dose lost an average of 28.7% of their body weight (32.3 kg or 71.2 lbs). The 9 mg dose produced 26.4% weight loss (29.1 kg). Placebo participants lost just 2.1%.

These figures represent the highest weight loss percentages reported in any completed phase 3 obesity trial. For context, tirzepatide achieved approximately 22.5% weight loss at 72 weeks in SURMOUNT-1, and CagriSema reached 22.7% at 68 weeks in REDEFINE 1.

More than half of participants on 12 mg lost at least 25% of their body weight. Nearly 40% lost 30% or more. Almost one in four (23.7%) achieved 35% or greater weight reduction.

Knee Osteoarthritis Pain Improvements

TRIUMPH-4 specifically enrolled people with knee osteoarthritis to study whether weight loss would translate into pain relief. The results were striking.

Baseline pain scores averaged 6.0 points on the WOMAC scale. After 68 weeks:

• The 9 mg group reduced pain by 4.5 points (75.8% improvement)
• The 12 mg group reduced pain by 4.4 points (74.3% improvement)
• Placebo reduced pain by 2.4 points (40.3% improvement)

One in eight participants treated with retatrutide reported complete resolution of knee pain by trial's end. Over two-thirds of treated participants achieved at least 70% pain reduction.

Cardiovascular Markers

Secondary endpoints showed reductions in systolic blood pressure (14.0 mmHg in the 12 mg group), non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein.

Safety Profile

The adverse event profile was consistent with other incretin-based therapies. Nausea affected 43.2% of the 12 mg group versus 10.7% on placebo. Diarrhea occurred in 33.1% versus 13.4%. Vomiting was reported by 20.9% versus 0%.

Treatment discontinuation due to adverse events was 18.2% in the 12 mg group, 12.2% in the 9 mg group, and 4.0% on placebo. Among participants with BMI ≥35, discontinuation rates were lower: 12.1% and 8.8% for the respective doses.

What Comes Next for Retatrutide?

Seven additional phase 3 trials are underway or reporting in 2026, covering type 2 diabetes, sleep apnea, chronic low back pain, MASH (metabolic dysfunction-associated steatotic liver disease), and cardiovascular outcomes. The TRIUMPH program has enrolled over 5,800 participants total. No FDA approval timeline has been announced, but results are expected throughout the year.

How Did Survodutide Perform in SYNCHRONIZE-1?

On April 28, 2026, Boehringer Ingelheim reported positive topline results from SYNCHRONIZE-1, a phase 3 trial testing survodutide in adults with obesity but without type 2 diabetes.

Survodutide is a dual-action peptide that activates both GLP-1 and glucagon receptors. The glucagon component differentiates it from semaglutide (GLP-1 only) and positions it as a direct competitor to Eli Lilly's retatrutide.

Weight Loss Data

After 76 weeks, participants on survodutide lost up to 16.6% of their body weight on average, compared with 3.2% on placebo. The trial met both co-primary endpoints:

• 85.1% of survodutide participants achieved at least 5% weight loss versus 38.8% on placebo
• Body composition analysis suggested most weight loss came from fat tissue, with lean mass contributing only a small proportion
• Waist circumference, a marker of visceral fat and cardiometabolic risk, showed statistically significant reductions

Safety

Gastrointestinal side effects were consistent with the GLP-1 class and generally mild to moderate, occurring more frequently during dose escalation. No new safety signals emerged.

MASH Pipeline

Survodutide is also being studied in LIVERAGE and LIVERAGE-Cirrhosis, two global phase 3 trials in adults with MASH and liver fibrosis. Results are expected later in 2026. Previous phase 2 data showed MASH improvement without fibrosis worsening in 47% to 62% of participants depending on dose, compared with 14% on placebo.

Full SYNCHRONIZE-1 data will be presented at the American Diabetes Association 2026 Scientific Sessions in June.

What Happened with CagriSema and Tirzepatide?

Novo Nordisk's CagriSema combines semaglutide 2.4 mg with cagrilintide 2.4 mg, an amylin analog, in a single weekly injection. The company filed a New Drug Application with the FDA in December 2025 based on REDEFINE 1 and REDEFINE 2 results. An FDA decision is expected by late 2026.

REDEFINE 4: The Head-to-Head Results

On February 23, 2026, Novo Nordisk announced results from REDEFINE 4, an 84-week open-label trial comparing CagriSema directly to tirzepatide 15 mg. The trial enrolled 809 participants with obesity and at least one comorbidity.

The results fell short of expectations:

• CagriSema achieved 23.0% weight loss
• Tirzepatide achieved 25.5% weight loss
• The primary endpoint of non-inferiority was not met

When accounting for treatment discontinuations, the gap widened: 20.2% for CagriSema versus 23.6% for tirzepatide.

Context and Next Steps

While REDEFINE 4 missed its primary endpoint, CagriSema still produced significant weight loss. The ongoing REDEFINE 11 trial is testing the drug's full weight-loss potential over a longer duration and is expected to report in the first half of 2027. A higher-dose CagriSema trial is planned for the second half of 2026.

The FDA review of CagriSema will be based on REDEFINE 1 (22.7% weight loss vs. placebo in obesity without diabetes) and REDEFINE 2 (15.7% weight loss in obesity with type 2 diabetes), not the head-to-head comparison.

When Did Ozempic Tablets Become Available?

On May 4, 2026, Novo Nordisk began shipping Ozempic (semaglutide) tablets to pharmacies across the United States. This marks the first time oral Ozempic has been available for adults with type 2 diabetes.

What Changed from Rybelsus?

Novo Nordisk previously sold oral semaglutide under the brand name Rybelsus in 3 mg, 7 mg, and 14 mg doses. The company reformulated the product with improved bioavailability, resulting in new dose strengths:

• 1.5 mg (replaces 3 mg starting dose)
• 4 mg (replaces 7 mg)
• 9 mg (replaces 14 mg)

The pills are smaller but deliver equivalent therapeutic effect. Rybelsus and Ozempic tablets are not interchangeable on a milligram-to-milligram basis.

Pricing

Self-pay pricing through NovoCare Pharmacy:

A supplemental application for a 25 mg Ozempic tablet is pending, with an FDA decision expected by the end of 2026.

Can Children Take Oral GLP-1 Medications?

On April 23, 2026, Novo Nordisk announced positive results from PIONEER TEENS, a phase 3a trial testing oral semaglutide in children and adolescents aged 10 to 17 with type 2 diabetes.

Trial Design and Results

PIONEER TEENS was a 52-week, randomized, double-blind, placebo-controlled study enrolling 132 participants. Children received oral semaglutide at maximum tolerated doses (3 mg, 7 mg, or 14 mg daily) plus background treatment with metformin, basal insulin, or both.

At 26 weeks, oral semaglutide demonstrated:

• A statistically significant 0.83 percentage point reduction in HbA1c versus placebo
• A safety profile consistent with previous semaglutide trials in adults

This is the first clinical trial of an oral GLP-1 receptor agonist in this age group.

Why This Matters

Globally, an estimated 14.6 million adolescents were living with type 2 diabetes in 2021. Projections suggest this number will reach 20.9 million by 2030. Type 2 diabetes in young people tends to progress faster and carries higher risks of early mortality than adult-onset disease. Current treatment options remain limited.

Novo Nordisk plans to file for regulatory approval to expand the Ozempic pill and Rybelsus labels to include pediatric patients in the US and EU during the second half of 2026.

What Research Peptides Are Approaching Clinical Trials?

Beyond the GLP-1 space, several research peptides are generating attention as they move toward or through early human studies.

CAQK for Traumatic Brain Injury

Aivocode, a biotechnology company founded by researchers Aman P. Mann, Sazid Hussain, and Erkki Ruoslahti, is preparing to seek FDA authorization for phase 1 clinical trials of CAQK, a four-amino-acid peptide (cysteine-alanine-glutamine-lysine) that targets injured brain tissue.

In animal studies published in EMBO Molecular Medicine in October 2025, CAQK administered intravenously after traumatic brain injury accumulated specifically in damaged regions, reduced inflammation and cell death, and improved functional recovery without apparent toxicity. The peptide worked in both mice and pigs, whose brains are structurally closer to humans.

"We observed less cell death and lower expression of inflammatory markers in the injured area," said lead author Dr. Mann. The findings represent the first demonstration that CAQK can produce therapeutic effects without requiring additional drugs.

P3 Peptide and Alzheimer's Disease

In a February 2026 commentary published in ChemBioChem, UC Santa Cruz professor Jevgenij Raskatov argued that a peptide called P3 (or Amyloid α) may contribute to Alzheimer's disease alongside the well-studied Amyloid beta.

P3 is a shorter peptide that forms when amyloid precursor protein is cleaved by α-secretase instead of β-secretase. Researchers have long assumed P3 is harmless and water-soluble. Raskatov's lab has shown that P3 readily forms oligomers and fibrils and is itself potentially neurotoxic.

"P3 is a distinct aggregating peptide that is itself potentially neurotoxic and may be contributing to Alzheimer's disease," Raskatov said. "This could turn Alzheimer's research on its head."

The overwhelming focus on Amyloid beta may explain why more than 400 clinical trials targeting it have largely failed to stop disease progression.

Pemvidutide for Liver Disease

Altimmune's pemvidutide, a dual GLP-1/glucagon receptor agonist, reported 48-week data from the IMPACT phase 2b trial in MASH (formerly NAFLD/NASH) in December 2025. The results showed sustained improvements in liver fibrosis markers:

• Enhanced Liver Fibrosis (ELF) score reductions of -0.49 to -0.58 versus +0.16 on placebo
• Liver Stiffness Measurement (LSM) reductions of -3.04 to -3.97 kPa versus -0.03 kPa on placebo

Pemvidutide holds FDA Breakthrough Therapy Designation for MASH and Fast Track Designation for alcohol-related liver disease. The company has aligned with the FDA on phase 3 trial parameters and will present full data at EASL Congress 2026, where the abstract was selected as "Best of EASL 2026."

Key Takeaways

• Retatrutide achieved 28.7% weight loss in TRIUMPH-4, the highest in any completed phase 3 obesity trial, with one in eight participants reporting complete knee pain resolution
• Survodutide hit 16.6% weight loss in SYNCHRONIZE-1, with MASH trial results expected later in 2026
• CagriSema lost the head-to-head comparison against tirzepatide in REDEFINE 4, though the FDA filing is based on separate placebo-controlled trials
• Ozempic tablets launched May 4 with new dosing (1.5 mg, 4 mg, 9 mg) at $149-$299/month
• Oral semaglutide showed positive results in children aged 10-17 with type 2 diabetes in PIONEER TEENS
• CAQK brain injury peptide is approaching phase 1 trials following positive animal studies

Frequently Asked Questions

What is the most effective weight loss peptide based on clinical trials?

Based on completed phase 3 trials, retatrutide has produced the highest average weight loss at 28.7% over 68 weeks in TRIUMPH-4. Tirzepatide has achieved approximately 22.5% at 72 weeks, and CagriSema reached 22.7% at 68 weeks. Retatrutide remains investigational with no FDA approval timeline announced.

When will retatrutide be FDA approved?

No approval timeline has been set. Seven phase 3 trials are ongoing or reporting results throughout 2026. Based on typical regulatory timelines, approval could potentially come in 2027 at the earliest, assuming successful trial outcomes.

Is oral semaglutide approved for children?

Not yet. PIONEER TEENS showed positive results in children aged 10-17 with type 2 diabetes, and Novo Nordisk plans to file for regulatory approval in the US and EU during the second half of 2026. An FDA decision would likely follow in 2027.

What is the difference between Ozempic tablets and Rybelsus?

Both contain oral semaglutide. Ozempic tablets use a reformulated version with improved bioavailability, resulting in lower dose strengths (1.5 mg, 4 mg, 9 mg) compared to Rybelsus (3 mg, 7 mg, 14 mg). The pills are smaller but therapeutically equivalent. They are not interchangeable on a milligram basis.

How does survodutide compare to tirzepatide?

Survodutide is a dual GLP-1/glucagon agonist, while tirzepatide is a dual GLP-1/GIP agonist. SYNCHRONIZE-1 showed 16.6% weight loss with survodutide at 76 weeks. Direct head-to-head comparison trials have not been conducted.

---

This content is for informational purposes only and is not medical advice. All peptides discussed are either investigational or approved only for specific indications. Consult a healthcare provider before starting any treatment. Regulatory status and clinical data are subject to change.

Sources

• Eli Lilly Investor Relations: TRIUMPH-4 Results
• Healio: Retatrutide Weight Loss and Knee OA Pain
• Boehringer Ingelheim: SYNCHRONIZE-1 Results
• Novo Nordisk: CagriSema NDA Filing
• GlobeNewswire: REDEFINE 4 Results
• Drugs.com: Ozempic Tablets Launch
• GlobeNewswire: PIONEER TEENS Results
• ScienceDaily: CAQK Brain Injury Peptide
• UC Santa Cruz News: P3 Peptide Alzheimer's Research
• HCPLive: Pemvidutide MASH Progress